Article citationsMore>>

Kedor, C., Listing, J., Zernicke, J., Weiß, A., Behrens, F., Blank, N., et al. (2020) Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): Phase II, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Investigator-Initiated Trial. Annals of the Rheumatic Diseases, 79, 1090-1097.
https://doi.org/10.1136/annrheumdis-2020-217155

has been cited by the following article:

• TITLE: Current Indications for IL-1 Inhibition in Rheumatology

  AUTHORS: Soukaina Zaher, Kawtar Nassar, Ahlam Ajerouassi, Wafae Rachidi, Saadia Janani

  KEYWORDS: Interleukin 1, Anti-Interleukin 1, Auto-Inflammatory Disease, Anakinra, Canakinumab, Rilonacept

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.15 No.4, November 28, 2025

  ABSTRACT: Interleukin-1 pro-inflammatory cytokines orchestrate local and systemic inflammatory responses in several diseases. Three therapeutic agents for reducing the activities of IL-1 are currently available. Conditions effectively treated with IL-1 blocking agents range from classical rheumatic diseases to autoinflammatory syndromes. In addition, IL-1 antagonism is also effective against other very common diseases, namely cardiovascular disease and type 2 diabetes, which are also co-morbidities, frequently found in patients with rheumatic diseases. Therefore, inhibition of IL-1 may provide clinical benefits beyond the efficacy of osteoarticular manifestations. The purpose of this article is to review the indications for anti-interleukins 1 in rheumatology.